Observational study demonstrates modest visual benefit from switching to aflibercept in treatment-resistant neovascular macular degeneration, suggesting an effective second-line option.
The study suggests that the possibility of switching eyes with treatment-resistant nAMD to aflibercept leads to a modest visual benefit compared with continuing first-line bevacizumab therapy.
No takes yet. Share an insight, caveat, or question.
Husum et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: